Upcoming Agents for the Treatment of Schizophrenia

Gervin, 2000, Adv Psychiatr Treat, 6, 332, 10.1192/apt.6.5.332

Haddad, 2004, Br J Psychiatry Suppl, 47, S80, 10.1192/bjp.184.47.s80

Kane, 1988, Arch Gen Psychiatry, 45, 789, 10.1001/archpsyc.1988.01800330013001

Meltzer, 2003, Arch Gen Psychiatry, 60, 82, 10.1001/archpsyc.60.1.82

Carlsson, 1963, Acta Pharmacol Toxicol (Copenh), 20, 140, 10.1111/j.1600-0773.1963.tb01730.x

Kongsamut, 1996, Eur J Pharmacol, 317, 417, 10.1016/S0014-2999(96)00840-0

Marquis, 2005, Schizophr Bull, 31, 305

Schotte, 1996, Psychopharmacology, 124, 57, 10.1007/BF02245606

Kyoto, 1999, Biochem Biophys Res Commun, 255, 367, 10.1006/bbrc.1999.0220

Allison, 1999, Am J Psychiatry, 156, 1686, 10.1176/ajp.156.11.1686

Barnes, 2003, J Psychopharmacol, 17, 365, 10.1177/0269881103174013

Simpson, 1970, Acta Psychiatr Scand, 212, 11, 10.1111/j.1600-0447.1970.tb02066.x

Weiden, 2008, J Clin Psychopharmacol, 28, S12, 10.1097/JCP.0b013e3181694f5a

Mori, 1989, Clin Eval, 17, 349

Lieberman, 2005, NEngl J Med, 353, 1209, 10.1056/NEJMoa051688

Mamo, 2008, Neuropsychopharmacology, 33, 298, 10.1038/sj.npp.1301409

Beasley Jr, 1996, Psychopharmacology, 124, 159, 10.1007/BF02245617

Young, 2006, Acta Psychiatr Scand, 114, 14, 10.1111/j.1600-0447.2006.00766.x